-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
11/20/2024
University of Washington
Researchers at Tempus partnered with the University of Washington to study the genomic alteration (GA) landscape of pure urothelial (UC) and histologic subtypes of bladder cancer.
This analysis promises to yield insight into variant histology bladder cancers to better understand their lack of clinical response, and potentially identify modes of therapeutic intervention.
This study was presented at the ASCO GU Cancers Symposium in 2024.
-
12/05/2024Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies
Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer. Discover the significant developments that are helping to shape clinical trials and improving patient outcomes in IO and hear perspectives from industry experts on the potential of emerging therapies.
Watch replay -
12/03/2024The future of immuno-oncology research: Challenges, innovations, and the role of data-driven solutions
This white paper offers an in-depth look at immuno-oncology (IO) research, emphasizing how data-driven research propels therapy development and enhances treatment efficacy. Download for a comprehensive analysis of the IO landscape, its projected market growth, and insights regarding pharmaceutical companies' strategic approaches to optimize therapeutic outcomes.
Read more -
11/26/2024Maximizing precision in pathology: the Critical Path approach
Enhancing tissue utilization, reducing turnaround time, and optimizing testing pathways with AI-driven insights.
Read more